Shanghai Haohai Biological Technology Co., Ltd. commences an Equity Buyback Plan for 4,004,530 shares, representing 2.25% of its issued share capital, under the authorization approved on February 14, 2020.
March 27, 2020 at 07:48 am EDT
Share
Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) commences share repurchases on March 27, 2020, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 14, 2020. As per the mandate, the company is authorized to repurchase up to 4,004,530 H shares, representing 2.25% of its issued shares. The authority shall expire at the earliest of the 2019 Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of February 14, 2020, the company had 137,800,000 class A shares in issue and 40,045,300 class H shares in issue.
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.
Shanghai Haohai Biological Technology Co., Ltd. commences an Equity Buyback Plan for 4,004,530 shares, representing 2.25% of its issued share capital, under the authorization approved on February 14, 2020.
SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD. 
